Summary of Product Characteristics for Evusheld - GOV.UK

Retrieved on: 2022-03-18 07:52:31

Tags for this article:

Clinical trials

COVID-19 pandemic in South Africa

COVID-19 vaccination in the United States

RNA vaccines

COVID-19 pandemic by country

Variants of SARS-CoV-2

SARS-CoV-2 Gamma variant

SARS-CoV-2 Beta variant

Severe acute respiratory syndrome coronavirus 2

SARS-CoV-2 Omicron variant

Pfizer-BioNTech COVID-19 vaccine

Variant of concern

Click the tags to see associated articles and topics

Summary of Product Characteristics for Evusheld - GOV.UK. View article details on HISWAI: https://www.gov.uk/government/publications/regulatory-approval-of-evusheld-tixagevimabcilgavimab/summary-of-product-characteristics-for-evusheld

Excerpt

Tixagevimab and cilgavimab are two recombinant human IgG1k monoclonal antibodies, with amino acid substitutions in the Fc regions to extend antibody ...

Article found on: www.gov.uk

View Original Article